Piotr Wysocki recently posted on LinkedIn:

“Qian H et al. conducted a randomized clinical trial (phase 2), which compared neoadjuvant chemo-hormonal therapy (NCHT) with androgen deprivation therapy (ADT) in locally advanced high-risk prostate cancer patients (Journal of Urology).

The study randomized 141 patients (2:1) to NHCT (6 cycles of docetaxel in 3-week intervals + ADT for 24 weeks or to ADT alone (24 weeks). The primary endpoint was a 3-year biochemical progression-free survival (bPFS). Secondary endpoints included pathological response, pathological downstaging, and minimal residual disease rates.

At a median follow-up of 53 months, NCHT significantly (p=0.002 – the authors have not provided HR calculations) improved 3-year bPFS survival rates (29%) compared to ADT alone (9.5%) and median bPFS – 17 months (NCHT) and 14 months (ADT).

In agreement with previous studies on neoadjuvant chemo-hormonal therapy in prostate cancer, the authors have not observed differences in pathological outcomes between NHCT and ADT groups.

The study by Qian H et al. suggests that neoadjuvant chemo-hormonal based on the combination of 6 cycles of docetaxel and 24 weeks of ADT can improve long-term outcomes by significantly decreasing the risk of biochemical relapse.

This very intriguing finding warrants further, larger phase III studies to validate the actual role of neoadjuvant chemo-hormonal treatment (also including ARPI) in high-risk prostate cancer patients.”

A Prospective Randomized Trial of Neoadjuvant Chemohormonal Therapy vs Hormonal Therapy in Locally Advanced Prostate Cancer Treated by Radical Prostatectomy

Authors: Hongyang Qian, Chenfei Chi, Thibault Tricard, Yinjie Zhu, Liang Dong, Yanqing Wang, Jianjun Sha, Jiayi Wang, Zehua Ma, Yan Wang, Jiazhou Liu, Baijun Dong, Jiahua Pan, Wei Xue

Source: Piotr Wysocki/LinkedIn

Piotr Wysocki leads the Clinical Oncology Department at University Hospital and the Faculty of Oncology at Jagiellonian University-Medical College in Krakow, Poland. As an advisor to the Polish Ministry of Health, he shapes the national cancer strategy.

His clinical expertise spans the systemic treatment of breast, gynecologic, and genitourinary cancers, with a focus on developing innovative metronomic chemotherapy-based therapies for advanced cancer patients who have undergone prior treatment.

Read other posts by Piotr Wysocki published on OncoDaily.